{"id":910448,"date":"2025-11-14T18:03:36","date_gmt":"2025-11-14T23:03:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/"},"modified":"2025-11-14T18:03:36","modified_gmt":"2025-11-14T23:03:36","slug":"hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/","title":{"rendered":"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Nov.  14, 2025  (GLOBE NEWSWIRE) &#8212; <strong>Class Action Attorney <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8uePJmqvHzusMiYHHhZFDPlfjK5S8PPkydfoC3ahgaUsnrHzrSUCv-tpKiuSB3g2mym1g-ZXk2BnYnR4h8ULnBLdzmW7EWPWRSoarY33R2R1J3EWOTDCwJOkvzp3P7hMIYgb4cUld5-wHZpOa-Rh5ExUbhTZENn688ptlJgEcY3cp7bpOIgO8mCqCCAG015NUPlI9HqMU4VzNT10WY208w==\" rel=\"nofollow\" target=\"_blank\"><u>Juan Monteverde<\/u><\/a><strong> with <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FdCG-zVcydOjmpOBqlMXJQVhjRH9ninzD-nZOW6hlF_AX_rsmDxOTnqRb-4Whd0hCxrGoFf3As3nF16GidT0NQpdnnlocxzvq2QOaWRLr-df2dBgs1yVGsm8JocosCGz\" rel=\"nofollow\" target=\"_blank\"><u>Monteverde &amp; Associates PC<\/u><\/a> (the \u201cM&amp;A Class Action Firm\u201d), has recovered millions of dollars for shareholders and is recognized as a <strong>Top 50\u00a0Firm <\/strong>in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the<strong>\u00a0Empire State Building<\/strong>\u00a0in New York City and is investigating<strong> Cidara Therapeutics, Inc. (NASDAQ: <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tc4w7C74HiSn-TAl-m9NWeHPm9HMVUS0efbtkUT9Vku6enjas3vMZCxaRIBBvn3iJ8zMnpy7MnWSSUxiK3-W3o5kS0LuKCwPKrIwfUgm6Mc=\" rel=\"nofollow\" target=\"_blank\"><strong>CDTX<\/strong><\/a><strong>) <\/strong>related to its sale to Merck Sharp &amp; Dohme LLC. Under the terms of the proposed transaction, Cidara shareholders will receive $221.50 per share in cash. <strong><u>Is it a fair deal?<\/u><\/strong><\/p>\n<p align=\"justify\">\n        <strong>Click here for more info\u00a0<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kdh4y79-C54_Yi3WCI1ud-z1uDyftu_Q-vtWxr-7nqKdd3mAJB25T9HFBNNbb7kivtuv1AxDTJQeZTlHxULaEQC8T7IzRMAWboLDX6d2I57_7_n0pljEnp493jFKroYLCQj_cV66WdLVfI_AFbjM80cOYIGIy1rr76NMpSop2UizuG6rCsMPaN8CU3mvS1rG\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>https:\/\/monteverdelaw.com\/case\/cidara-therapeutics-inc\/<\/strong><br \/>\n        <\/a><br \/>\n        <strong>.<\/strong><br \/>\n        <strong>It is free and there is no cost or obligation to you.<\/strong>\n      <\/p>\n<p>\n        <strong>NOT ALL LAW FIRMS ARE EQUAL.\u00a0<\/strong>Before you hire a law firm, you should talk to a lawyer and ask:<\/p>\n<ol style=\"list-style-type:decimal\">\n<li>Do you file class actions and go to Court?<\/li>\n<li>When was the last time you recovered money for shareholders?<\/li>\n<li>What cases did you recover money in and how much?<\/li>\n<\/ol>\n<p>\n        <strong>About Monteverde &amp; Associates PC<\/strong>\n      <\/p>\n<p>Our firm litigates and has recovered money for shareholders\u2026and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S.\u00a0Supreme Court.\u00a0<\/p>\n<p>\n        <strong>No one is above the law.<\/strong> If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x79SFI4_SZO6uNSCmkv6Y9VfaPWc3XNzL7-oCKRL4iB5CRKIb5enzu95xelx80zHZsu3S6aplD4NPhwg55D5rMABpP9oLSAHH568DHJ0wYMTe70_r1BkewEVD-CAefyNJPjtopX0T0LigpxQnzNtgpterjiay4euTC1goScotd8HPay9VOgvj5DQ-yda6MWO\" rel=\"nofollow\" target=\"_blank\"><strong><u>website<\/u><\/strong><\/a> or contact Juan Monteverde, Esq. either via e-mail at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y9PBjQeGVeBgb05Dd3b86czu7nuBcFLtvZ85N1LXhzUNwRWiU4WVqdqnhA4IbNNZwVsG9kwa9zTbs-SjURZZnM6gIb5aenwyaaeRp-rH8j4-2qIfRFEYmpgPOn9SSRHr\" rel=\"nofollow\" target=\"_blank\"><strong><u>jmonteverde@monteverdelaw.com<\/u><\/strong><\/a> or by telephone at (212) 971-1341.<\/p>\n<p>Contact:<br \/>Juan Monteverde, Esq.<br \/>MONTEVERDE &amp; ASSOCIATES PC<br \/><strong>The Empire State Building<\/strong><br \/>350 Fifth Ave. Suite 4740<br \/>New York, NY 10118<br \/>United States of America<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y9PBjQeGVeBgb05Dd3b86czu7nuBcFLtvZ85N1LXhzWVB-G0iLdHAhcDmV-kcqk3Mz0q-wmRDgUVEsn00_q3Sx3Za2-buCoP_oP1giHATwYrBMOVJzfDdoWrXvuKCOhV\" rel=\"nofollow\" target=\"_blank\"><u>jmonteverde@monteverdelaw.com<\/u><\/a><br \/>Tel: (212) 971-1341<\/p>\n<p>Attorney Advertising. (C) 2025 Monteverde &amp; Associates PC.\u00a0The law firm responsible for this advertisement is Monteverde &amp; Associates PC (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XVlw0PGhKzZOTcyZ_xPg50GiWun3GA46gmBr3L_1Eu6VSfK8cIqDWGQNo0Qe2rthaahQiDwi1VIf5vf1NFFnsyEWgF1283e-lxgdrZ6lwEeZITVnym2zd6FL4V69qney7z4o9cYNFndn8Fgz06WdOwm8ECbKTDiXWiN_GEcr2N9QE_BdftSzY0PtHN2ov-6CvyF2A0wbZ0TwoJ9-mrX2_JdCDmBjfkraJ-YeiaTnBWo=\" rel=\"nofollow\" target=\"_blank\"><u>www.monteverdelaw.com<\/u><\/a>). Prior results do not guarantee a similar outcome with respect to any future matter.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjM0OCM3MjY1ODEzIzIxODQzNTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWYwOTE4NGItMWRkNS00ODEyLTllOWItNTZkZmY3OGQzY2M3LTExOTU5MTMtMjAyNS0xMS0xNC1lbg==\/tiny\/Monteverde-Associates-PC.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) &#8212; Class Action Attorney Juan Monteverde with Monteverde &amp; Associates PC (the \u201cM&amp;A Class Action Firm\u201d), has recovered millions of dollars for shareholders and is recognized as a Top 50\u00a0Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the\u00a0Empire State Building\u00a0in New York City and is investigating Cidara Therapeutics, Inc. (NASDAQ: CDTX) related to its sale to Merck Sharp &amp; Dohme LLC. Under the terms of the proposed transaction, Cidara shareholders will receive $221.50 per share in cash. Is it a fair deal? Click here for more info\u00a0 https:\/\/monteverdelaw.com\/case\/cidara-therapeutics-inc\/ . It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-910448","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) &#8212; Class Action Attorney Juan Monteverde with Monteverde &amp; Associates PC (the \u201cM&amp;A Class Action Firm\u201d), has recovered millions of dollars for shareholders and is recognized as a Top 50\u00a0Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the\u00a0Empire State Building\u00a0in New York City and is investigating Cidara Therapeutics, Inc. (NASDAQ: CDTX) related to its sale to Merck Sharp &amp; Dohme LLC. Under the terms of the proposed transaction, Cidara shareholders will receive $221.50 per share in cash. Is it a fair deal? Click here for more info\u00a0 https:\/\/monteverdelaw.com\/case\/cidara-therapeutics-inc\/ . It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE &hellip; Continue reading &quot;$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-14T23:03:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjM0OCM3MjY1ODEzIzIxODQzNTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)\",\"datePublished\":\"2025-11-14T23:03:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\\\/\"},\"wordCount\":347,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjM0OCM3MjY1ODEzIzIxODQzNTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\\\/\",\"name\":\"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjM0OCM3MjY1ODEzIzIxODQzNTk=\",\"datePublished\":\"2025-11-14T23:03:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjM0OCM3MjY1ODEzIzIxODQzNTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjM0OCM3MjY1ODEzIzIxODQzNTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/","og_locale":"en_US","og_type":"article","og_title":"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX) - Market Newsdesk","og_description":"NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) &#8212; Class Action Attorney Juan Monteverde with Monteverde &amp; Associates PC (the \u201cM&amp;A Class Action Firm\u201d), has recovered millions of dollars for shareholders and is recognized as a Top 50\u00a0Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the\u00a0Empire State Building\u00a0in New York City and is investigating Cidara Therapeutics, Inc. (NASDAQ: CDTX) related to its sale to Merck Sharp &amp; Dohme LLC. Under the terms of the proposed transaction, Cidara shareholders will receive $221.50 per share in cash. Is it a fair deal? Click here for more info\u00a0 https:\/\/monteverdelaw.com\/case\/cidara-therapeutics-inc\/ . It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE &hellip; Continue reading \"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-14T23:03:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjM0OCM3MjY1ODEzIzIxODQzNTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)","datePublished":"2025-11-14T23:03:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/"},"wordCount":347,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjM0OCM3MjY1ODEzIzIxODQzNTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/","name":"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjM0OCM3MjY1ODEzIzIxODQzNTk=","datePublished":"2025-11-14T23:03:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjM0OCM3MjY1ODEzIzIxODQzNTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjM0OCM3MjY1ODEzIzIxODQzNTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cidara-therapeutics-inc-nasdaq-cdtx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=910448"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910448\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=910448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=910448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=910448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}